To further build upon its drug research and development capabilities, NeurOp has formed consulting relationships with a number of experts in neuropharmacology, drug chemistry, toxicology, and pre-clinical and clinical studies. Our scientific and clinical advisors regularly consult with us on research programs, the design of our studies, and a variety of scientific and technical issues.
Bruce Burnett, PhD
is the Quality Assurance Director at the Laboratory for Cell and Gene Medicine at Stanford University. Bruce Burnett has a distinguished career in regulatory affairs, particularly in the pharmaceutical industry. He has held various positions, including Chief of the Office of Regulatory Affairs at the National Institutes of Health (NIH) and Head of US Regulatory and Medical Affairs at InflaRx. His extensive experience includes oversight of regulatory and quality services, education, regulatory consultation, support for regulatory submissions, quality control/assurance activities, and guidance on GMP, GLP, and GCP.
Jeff Geng
Bio coming soon
Daniel Laskowitz, MD
is a Professor of Neurology in the Duke University School of Medicine and is an attending neurologist in the neuro-intensive care center of Duke University hospital. He is director of the Duke Clinical Research Institute in the Department of Neurology and has deep experience in clinical trial design and execution of clinical trials centered on brain injury. He has over 25 years of experience treating and studying acute neuronal injury.
Erin O’Reilly, PhD RAC
provides regulatory and medical writing services to the pharmaceutical industry. She has more than 20 years’ experience as a regulatory professional with skills in protocol development, regulatory strategy, regulatory writing, GMP, and GCP. She collaborates with large companies, small start-ups, and contract research organizations.
Jesse Troy, PhD
is an Associate Professor of Biostatistics & Bioinformatics in the Duke University School of Medicine. He is a highly respected biostatistician with deep experience in novel clinical trial design.
Roy Twyman, MD
has two decades experience in neuroscience pharmaceutical drug development, most recently as senior vice president at Janssen Pharmaceutical Research & Development LLC, where he was the Alzheimer’s disease area leader in the Neuroscience Therapeutic Area. Dr. Twyman has served on advisory committees and panels of the U.S. Food and Drug Administration and the Institute of Medicine.